# Gradient Denervation Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gradient-denervation-technologies

- Industry: Pharmaceuticals
- Headquarters: Paris, France
- Website: www.gradientdenervation.com
- Total disclosed funding: $19M
- Latest round: Series A (Sep 7, 2023)
- Investors on record: 3

## About

Gradient Denervation Technologies, based in Paris, France, focuses on developing innovative medical devices for treating pulmonary hypertension, with a primary product designed to target physiological mechanisms associated with this condition.Founded in 2020, Gradient Denervation Technologies specializes in creating medical solutions for pulmonary hypertension. The company has engaged in two investment rounds, with its most recent funding round occurring on September 7, 2023, where they raised EUR 14 million in a Series A round led by Asabys Partners, along with participation from Sofinnova Partners and Thuja Capital. The CEO of the company is Martin Grasse.Gradient Denervation Technologies develops innovative medical devices aimed at treating pulmonary hypertension, notably the Gradient device. This investigational product targets specific physiological mechanisms associated with pulmonary hypertension, aiming to enhance the quality of life for patients. The company serves healthcare providers and research institutions across various regions, focusing on areas where pulmonary hypertension is prevalent. Currently, specific details regarding market entry or product release timelines remain undisclosed as the company is still in the investigational stage.Gradient Denervation Technologies has not disclosed specific revenue figures or transaction structures. However, their business model likely involves partnerships with healthcare institutions and research organizations for the development and potential commercialization of their device. Sales may be structured through B2B agreements, allowing healthcare providers access to the Gradient device via collaborative partnerships or clinical trials. Pricing strategies and financial models have not been disclosed, thus no precise information on product pricing or revenue generation methods is available.Following the recent Series A funding round, which raised EUR 14 million on September 7, 2023, Gradient Denervation Technologies plans to utilize this capital to advance the clinical development of its product offerings. The company aims to introduce new solutions for pulmonary hypertension and will focus on expanding its presence in specific regions affected by this condition. Targeted geographic regions for expansion will be detailed as strategies evolve.

## Funding rounds

- Series A, Sep 7, 2023, $15M — Sofinnova Partners, Thuja Capital, Asabys Partners
- Seed, Feb 1, 2020, $3.8M — Sofinnova Partners

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed, Series A
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A
- Asabys Partners (https://capitalatlas.ai/funds/asabys-partners) — Series A